Literature DB >> 8443801

Preliminary mapping of the deleted region of chromosome 9 in bladder cancer.

P Cairns1, M E Shaw, M A Knowles.   

Abstract

Inactivation of a suppressor gene by deletion of chromosome 9 is a candidate initiating event in bladder carcinogenesis. We have used 13 polymorphic markers spanning the length of chromosome 9 in order to map the region of deletion in human bladder carcinomas. In the majority of tumors loss of heterozygosity was found at all informative sites along the chromosome, indicating deletion of the entire chromosome. Nine tumors had selective deletions of chromosome 9. Mapping of the deleted region in these tumors suggests that the target gene is located between D9S22 at 9q22 and D9S18 at 9p12-13.

Entities:  

Mesh:

Year:  1993        PMID: 8443801

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

1.  Breakpoint junctions of chromosome 9p deletions in two human glioma cell lines.

Authors:  H M Pomykala; S K Bohlander; P L Broeker; O I Olopade; M O Díaz
Journal:  Mol Cell Biol       Date:  1994-11       Impact factor: 4.272

Review 2.  Genetics of bladder cancer.

Authors:  K K Saran; D Gould; C J Godec; R S Verma
Journal:  J Mol Med (Berl)       Date:  1996-08       Impact factor: 4.599

Review 3.  Molecular and immunopathology studies of oncogenes and tumor-suppressor genes in bladder cancer.

Authors:  C Cordon-Cardo; J Sheinfeld
Journal:  World J Urol       Date:  1997       Impact factor: 4.226

4.  Structure, function, and chromosome mapping of the growth-suppressing human homologue of the murine gas1 gene.

Authors:  G Del Sal; L Collavin; M E Ruaro; P Edomi; S Saccone; G D Valle; C Schneider
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-01       Impact factor: 11.205

Review 5.  Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression.

Authors:  David J McConkey; Sangkyou Lee; Woonyoung Choi; Mai Tran; Tadeusz Majewski; Sooyong Lee; Arlene Siefker-Radtke; Colin Dinney; Bogdan Czerniak
Journal:  Urol Oncol       Date:  2010 Jul-Aug       Impact factor: 3.498

6.  Measurement of relative copy number of CDKN2A/ARF and CDKN2B in bladder cancer by real-time quantitative PCR and multiplex ligation-dependent probe amplification.

Authors:  Joanne S Aveyard; Margaret A Knowles
Journal:  J Mol Diagn       Date:  2004-11       Impact factor: 5.568

7.  The relation of mutant p53 accumulation in transitional cell carcinoma of bladder with pathological stage, grade, recurrence and survival.

Authors:  C O Yeniyol; T Süelözgen; E Vardar; S Sural; H Postaci; A R Ayder
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

Review 8.  Bladder cancer: the molecular progression to invasive disease.

Authors:  A R Simoneau; P A Jones
Journal:  World J Urol       Date:  1994       Impact factor: 4.226

9.  MTS1/p16/CDKN2 lesions in primary glioblastoma multiforme.

Authors:  T Moulton; G Samara; W Y Chung; L Yuan; R Desai; M Sisti; J Bruce; B Tycko
Journal:  Am J Pathol       Date:  1995-03       Impact factor: 4.307

10.  Detection of chromosomal imbalances in transitional cell carcinoma of the bladder by comparative genomic hybridization.

Authors:  C Voorter; S Joos; P P Bringuier; M Vallinga; P Poddighe; J Schalken; S du Manoir; F Ramaekers; P Lichter; A Hopman
Journal:  Am J Pathol       Date:  1995-06       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.